Major pharmaceutical company GlaxoSmithKline has made a strong defence of diabetes drug Avandia by issuing a detailed 30-page rebuttal to criticism levied by a US committee. The drugmaker claimed that a senate finance committee report was neither accurate, balanced or complete. The company also rejected allegations that it had covered up safety data, and said that the Senate reported included glaring omissions.
The Food and Drug Administration yesterday called for patients succeeding with Avandia to keep taking the diabetes drug, ahead of an advisory panel in July. Glaxo made it clear that they had studied the efficiency of the drug and how safe it was, and been transparent in communicating this data to medical professionals, regulators and governments.
Glaxo reportedly commented: “The safety of Avandia should be judged in light of all available scientific data with emphasis on long-term prospective studies.”

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Public Health England considers low carb approach for type 2 diabetes

The low carb approach is being considered by the government to be…

Type 2 diabetes found to be a ‘significant risk factor’ among stroke victims

More evidence has been published which supports that diabetes is a “significant…

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…